History of the development of antiemetic guidelines at Mayo Clinic Rochester.
暂无分享,去创建一个
P. Southorn | D. Farley | C. Loprinzi | S. Alberts | T. Johnson | L. Hanson | P A Southorn | D. Betcher | C L Loprinzi | S R Alberts | R E Grady | B J Christensen | L J Hanson | D R Farley | J K Broers | D L Betcher | T M Johnson | E A Perez | B. Christensen | R. E. Grady | E. A. Perez | J. Broers
[1] L. Goedhals,et al. Oral granisetron alone and in combination with dexamethasone: a double-blind randomized comparison against high-dose metoclopramide plus dexamethasone in prevention of cisplatin-induced emesis. The Granisetron Study Group. , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] J. Carmichael,et al. Comparison of granisetron alone and granisetron plus dexamethasone in the prophylaxis of cytotoxic-induced emesis. , 1994, British Journal of Cancer.
[3] D. Currow,et al. Use of ondansetron in palliative medicine. , 1997, Journal of pain and symptom management.
[4] J. Carles,et al. Comparison of three protracted antiemetic regimens for the control of delayed emesis in cisplatin-treated patients. , 1992, European journal of cancer.
[5] D. Ettinger,et al. Single-dose oral granisetron has equivalent antiemetic efficacy to intravenous ondansetron for highly emetogenic cisplatin-based chemotherapy. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] M. Kris,et al. Reduction of cisplatin-induced emesis by a selective neurokinin-1-receptor antagonist. L-754,030 Antiemetic Trials Group. , 1999, The New England journal of medicine.
[7] J. Verweij,et al. Optimum anti-emetic therapy for cisplatin induced emesis over repeat courses: ondansetron plus dexamethasone compared with metoclopramide, dexamethasone plus lorazepam. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] J. Hainsworth,et al. The role of the 5-HT3 antagonists ondansetron and dolasetron in the control of delayed onset nausea and vomiting in patients receiving moderately emetogenic chemotherapy. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.
[9] N. Gebbia,et al. Oral granisetron with or without methylprednisolone versus metoclopramide plus methylprednisolone in the management of delayed nausea and vomiting induced by cisplatin‐based chemotherapy. A prospective randomized trial , 1995, Cancer.
[10] A. Markham,et al. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. , 1996, Drugs.
[11] M. Nicolson,et al. Does dexamethasone enhance control of acute cisplatin induced emesis by ondansetron? , 1991, BMJ.
[12] F. Roila. Ondansetron versus granisetron, both combined with dexamethasone, in the prevention of cisplatin-induced emesis. Italian Group of Antiemetic Research. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] J. Porta,et al. Antiemetic efficacy of subcutaneous 5-HT3 receptor antagonists in terminal cancer patients. , 1998, Journal of Pain and Symptom Management.
[14] M. Kris,et al. Use of an NK1 receptor antagonist to prevent delayed emesis after cisplatin. , 1997, Journal of the National Cancer Institute.
[15] M. Kris,et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] D. Johnston,et al. Use of dexamethasone and granisetron in the control of delayed emesis for patients who receive highly emetogenic chemotherapy. National Cancer Institute of Canada Clinical Trials Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] M. Kris,et al. Assuring the optimal use of serotonin antagonist antiemetics: the process for development and implementation of institutional antiemetic guidelines at Memorial Sloan-Kettering Cancer Center. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] Y. Akahane,et al. Transmission of HCV between spouses , 1992, The Lancet.
[19] D. Amadori,et al. Prevention of cisplatin-induced emesis: a double-blind multicenter randomized crossover study comparing ondansetron and ondansetron plus dexamethasone. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] D. Greenblatt,et al. Current Status of Benzodiazepines , 1983 .
[21] Philpot Cr. ONDANSETRON BY SUBCUTANEOUS INFUSION , 1993 .
[22] F. Roila,et al. Ondansetron versus Methoclopramide, both combined with Dexamethasone, in the preventions of Cispltin induced delayed emesis. , 1997 .
[23] D. Kerr,et al. Ondansetron compared with metoclopramide in the control of emesis and quality of life during repeated chemotherapy for breast cancer. , 1992, Oncology.
[24] M. Aapro,et al. Ondansetron plus dexamethasone is superior to ondansetron alone in the prevention of emesis in chemotherapy-naive and previously treated patients. Swiss Group for Clinical Cancer Research (SAKK). , 1994, Annals of oncology : official journal of the European Society for Medical Oncology.
[25] T. Högberg,et al. Efficacy and tolerability of tropisetron in comparison with a combination of tropisetron and dexamethasone in the control of nausea and vomiting induced by cisplatin-containing chemotherapy. , 1994, European journal of cancer.
[26] D. Greenblatt,et al. Drug therapy. Current status of benzodiazepines. , 1983, The New England journal of medicine.
[27] A. Favero,et al. Ondansetron + dexamethasone vs metoclopramide + dexamethasone + diphenhydramine in prevention of cisplatin-induced emesis , 1992 .
[28] E. Perez,et al. Comparison of single-dose oral granisetron versus intravenous ondansetron in the prevention of nausea and vomiting induced by moderately emetogenic chemotherapy: a multicenter, double-blind, randomized parallel study. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] J. Hainsworth,et al. A randomized, double-blind comparison of intravenous ondansetron alone and in combination with intravenous dexamethasone in the prevention of high-dose cisplatin-induced emesis. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] M. Kris,et al. Prevention of acute emesis in cancer patients following high-dose cisplatin with the combination of oral dolasetron and dexamethasone. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.